275 related articles for article (PubMed ID: 28964549)
1. Evidence-Based Precision Oncology with the Cancer Targetome.
Blucher AS; Choonoo G; Kulesz-Martin M; Wu G; McWeeney SK
Trends Pharmacol Sci; 2017 Dec; 38(12):1085-1099. PubMed ID: 28964549
[TBL] [Abstract][Full Text] [Related]
2. [Precision oncology and molecular tumor boards].
Mack E; Horak P; Fröhling S; Neubauer A
Inn Med (Heidelb); 2024 May; 65(5):462-471. PubMed ID: 38652307
[TBL] [Abstract][Full Text] [Related]
3. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).
Mateo J; Chakravarty D; Dienstmann R; Jezdic S; Gonzalez-Perez A; Lopez-Bigas N; Ng CKY; Bedard PL; Tortora G; Douillard JY; Van Allen EM; Schultz N; Swanton C; André F; Pusztai L
Ann Oncol; 2018 Sep; 29(9):1895-1902. PubMed ID: 30137196
[TBL] [Abstract][Full Text] [Related]
4. Delivering on the promise of precision cancer medicine.
Berger MF; Van Allen EM
Genome Med; 2016 Oct; 8(1):110. PubMed ID: 27782852
[No Abstract] [Full Text] [Related]
5. Precision medicine in pediatric oncology.
Forrest SJ; Geoerger B; Janeway KA
Curr Opin Pediatr; 2018 Feb; 30(1):17-24. PubMed ID: 29189430
[TBL] [Abstract][Full Text] [Related]
6. Perspective on Precision Medicine in Oncology.
Johnson TM
Pharmacotherapy; 2017 Sep; 37(9):988-989. PubMed ID: 28632968
[TBL] [Abstract][Full Text] [Related]
7. Disparity between Inter-Patient Molecular Heterogeneity and Repertoires of Target Drugs Used for Different Types of Cancer in Clinical Oncology.
Zolotovskaia MA; Sorokin MI; Petrov IV; Poddubskaya EV; Moiseev AA; Sekacheva MI; Borisov NM; Tkachev VS; Garazha AV; Kaprin AD; Shegay PV; Giese A; Kim E; Roumiantsev SA; Buzdin AA
Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32111026
[TBL] [Abstract][Full Text] [Related]
8. Progress in precision therapy in pediatric oncology.
O'Donohue T; Farouk Sait S; Glade Bender J
Curr Opin Pediatr; 2023 Feb; 35(1):41-47. PubMed ID: 36377257
[TBL] [Abstract][Full Text] [Related]
9. Precision Medicine in Oncology II: Economics of Targeted Agents and Immuno-Oncology Drugs.
Huntington SF; Davidoff AJ; Gross CP
J Clin Oncol; 2020 Feb; 38(4):351-358. PubMed ID: 31804866
[No Abstract] [Full Text] [Related]
10. "Personalized Cancer Therapy": A Publicly Available Precision Oncology Resource.
Kurnit KC; Bailey AM; Zeng J; Johnson AM; Shufean MA; Brusco L; Litzenburger BC; Sánchez NS; Khotskaya YB; Holla V; Simpson A; Mills GB; Mendelsohn J; Bernstam E; Shaw K; Meric-Bernstam F
Cancer Res; 2017 Nov; 77(21):e123-e126. PubMed ID: 29092956
[TBL] [Abstract][Full Text] [Related]
11. Pediatric oncology enters an era of precision medicine.
Seibel NL; Janeway K; Allen CE; Chi SN; Cho YJ; Glade Bender JL; Kim A; Laetsch TW; Irwin MS; Takebe N; Tricoli JV; Parsons DW
Curr Probl Cancer; 2017; 41(3):194-200. PubMed ID: 28343740
[TBL] [Abstract][Full Text] [Related]
12. Universal Genomic Testing: The next step in oncological decision-making or a dead end street?
Holch JW; Metzeler KH; Jung A; Riedmann K; Jost PJ; Weichert W; Kirchner T; Heinemann V; Westphalen CB
Eur J Cancer; 2017 Sep; 82():72-79. PubMed ID: 28648701
[TBL] [Abstract][Full Text] [Related]
13. Clonotyping for precision oncology.
Dang HX; Maher CA
Drug Discov Today; 2015 Dec; 20(12):1464-9. PubMed ID: 26494143
[TBL] [Abstract][Full Text] [Related]
14. Path toward Precision Oncology: Review of Targeted Therapy Studies and Tools to Aid in Defining "Actionability" of a Molecular Lesion and Patient Management Support.
Chae YK; Pan AP; Davis AA; Patel SP; Carneiro BA; Kurzrock R; Giles FJ
Mol Cancer Ther; 2017 Dec; 16(12):2645-2655. PubMed ID: 29203694
[TBL] [Abstract][Full Text] [Related]
15. Precision Oncology in Pediatric Cancer Surgery.
Lee WG; Kim ES
Surg Oncol Clin N Am; 2024 Apr; 33(2):409-446. PubMed ID: 38401917
[TBL] [Abstract][Full Text] [Related]
16. Next-Generation Sequencing in Oncology in the Era of Precision Medicine.
Blumenthal GM; Mansfield E; Pazdur R
JAMA Oncol; 2016 Jan; 2(1):13-4. PubMed ID: 26540172
[No Abstract] [Full Text] [Related]
17. Integrating proteomics into precision oncology.
Wahjudi LW; Bernhardt S; Abnaof K; Horak P; Kreutzfeldt S; Heining C; Borgoni S; Becki C; Berg D; Richter D; Hutter B; Uhrig S; Pfütze K; Leichsenring J; Glimm H; Brors B; von Kalle C; Stenzinger A; Korf U; Fröhling S; Wiemann S
Int J Cancer; 2021 Mar; 148(6):1438-1451. PubMed ID: 32949162
[TBL] [Abstract][Full Text] [Related]
18. Harnessing the potential of reverse-phase protein array technology: Advancing precision oncology strategies.
Masuda M; Nakagawa R; Kondo T
Cancer Sci; 2024 May; 115(5):1378-1387. PubMed ID: 38409909
[TBL] [Abstract][Full Text] [Related]
19. Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S; Sun SQ; Huang KL; Oh C; Bailey MH; Varghese R; Wyczalkowski MA; Ning J; Tripathi P; McMichael JF; Johnson KJ; Kandoth C; Welch J; Ma C; Wendl MC; Payne SH; Fenyö D; Townsend RR; Dipersio JF; Chen F; Ding L
Genome Med; 2018 Jul; 10(1):60. PubMed ID: 30053901
[TBL] [Abstract][Full Text] [Related]
20. Ushering in the next generation of precision trials for pediatric cancer.
DuBois SG; Corson LB; Stegmaier K; Janeway KA
Science; 2019 Mar; 363(6432):1175-1181. PubMed ID: 30872517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]